[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
June 17, 1983

No sneezing—or dozing— seen with new H1 blocker

JAMA. 1983;249(23):3151-3152. doi:10.1001/jama.1983.03330470009003

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


It is now possible for some allergy patients to breathe more easily and remain alert, as demonstrated by European clinical trials of a potent new antihistamine, terfenadine. The drug does not produce sedation or other adverse effects associated with older antihistamine preparations. In addition, there are no apparent contraindications for its use in adult allergy sufferers, nor have any carcinogenic, mutagenic, or teratogenic effects been seen in animals.

Terfenadine, manufactured by Merrell Dow Pharmaceuticals, Inc, Cincinnati, is like other antihistamines—an H1 receptor antagonist; that is, it specifically blocks the chain of cellular events following the release of histamine that triggers the typical symptoms of acute and perennial rhinitis and allergic dermatitis. However, terfenadine does not affect the CNS, as indicated by a series of clinical trials reported at a Milan symposium to introduce the agent in Italy.